search
Back to results

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Primary Purpose

Digestive System Neoplasms

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
LP002
Cisplatin
Fluorouracil
OH2 oncolytic virus
Sponsored by
Taizhou HoudeAoke Biomedical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Digestive System Neoplasms

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Understood and signed an informed consent form.
  • Age ≥ 18 and ≤ 75 years old, male or female.
  • Has histologically confirmed diagnosis of:

Malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment for Arm I-A.

Malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments for Arm I-B.

Metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive for Arm I-C.

Gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive for Arm I-D.

Advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments and has suitable lesions for intratumoral injection for Arm I-E.

  • Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Score.
  • Life expectancy ≥ 3 months.
  • Has at least one measurable extracranial lesion according to RECIST1.1 (except Arm-D).
  • Has sufficient organ and bone marrow function to meet the following laboratory examination standards:

    1. Blood routine: absolute neutrophil count (ANC)≥1.5×10^9/L; while blood cell count (WBC)≥3×10^9/L; platelet count (PLT)≥100×10^9/L;hemoglobin (HGB)≥90 g/L;
    2. Renal function: Serum creatinine (Scr) ≤1.5×ULN;
    3. Liver function: TBIL≤1.5×ULN; Patients without liver metastases require alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN. Patients with liver metastases require: ALT and AST≤5×ULN;
    4. The coagulation function is adequate, which is defined as the international normalized ratio (INR) ≤ 2×ULN; or activated partial thromboplastin time (APTT)≤ 1.5×ULN;
  • Reproductive men and women of childbearing age are willing to take effective contraceptive measures from signing the informed consent form to 3 months after the last administration of the trial drug.
  • Willing to provide tissue samples for PD-L1 biomarker analysis.

Exclusion Criteria:

  • Suffered from other malignant tumors in the past 5 years,except those with low risk of metastasis and death (5-year survival rate >90%), for instance, skin basal cell carcinoma, squamous cell carcinoma, and carcinoma in situ from cervix or other regions that have been adequately treated);
  • Had prior treatment with any anti-programmed cell death-1 (PD-1), or PD-ligand 1 (PD-L1) or CTLA-4 agent or other immune checkpoint inhibition therapies.
  • has active or a history (with high chance of recurrence) of autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, vasculitis, nephritis, except: Type I Diabetes being treated with fixed dose of insulin, hypothyroidism or Hashimoto's thyroiditis that can be controlled only by hormone replacement therapy, skin diseases that do not require systemic treatment (such as eczema, rash covering <10% body surface area, psoriasis without ocular symptoms).
  • Expected to undergo major surgery during the study treatment or within 28 days before the first administration of the study drug.
  • Has received systemic corticosteroids or other immunosuppressive drugs within 2 weeks before the first administration of the study drug, excluding:

    1. Nasal spray, inhalation or other local glucocorticoids.
    2. Short-term (≤ 7 days) use of glucocorticoids as a preventive medication for allergic reactions or as a therapeutic medication for non-autoimmune diseases.
  • Has active digestive ulcer, incomplete intestinal obstruction, active gastrointestinal hemorrhage or perforation.
  • Has active interstitial pneumonia, pulmonary fibrosis, acute pulmonary disorders, acute radiation pneumonitis,et al.
  • Has uncontrolled systemic diseases, for instance, cardiovascular and cerebrovascular disease, diabetes, tuberculosis.
  • Has a history of HIV infection, or other acquired or innate immune deficiency disorders, or a history of organ or stem-cell transplantation.
  • Has active chronic HBV or HCV infection, except those with HBV DNA viral load ≤500 IU/mL or <10^3 copies/mL, or HCV RNA negative after adequate treatment.
  • Has severe infection within 4 weeks or active infection requiring IV infusion of antibiotics within 2 weeks prior to the first administration of the study drug.
  • Known to be allergic to macromolecular protein agents or monoclonal antibody; Known to has a history of severe allergies to any of the components in the study drug;
  • Has participated in other clinical trial within 4 weeks before the first administration of the study drug.
  • Alcohol dependence or drug abuse within recent one year.
  • Has a history of confirmed neurological or mental disorders, such as epilepsy, dementia; or with poor compliance; or the presence of peripheral neurological disorders.
  • Has brain metastasis with symptoms.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
  • Has received a live vaccine within 30 days prior to the first dose of trial treatment.
  • Other reasons disqualifying the entering of this study based on the evaluation of the investigators.

Sites / Locations

  • Cancer Hospital Chinese Academy of Medical SciencesRecruiting
  • Henan Cancer Hospital & InsitituteRecruiting
  • Hubei Cancer Hospital & InsitituteRecruiting
  • Liaoning Cancer Hospital & InsitituteRecruiting
  • The First Affiliated Hospital. Zhejiang University School Of MedicineRecruiting
  • The First Affiliated Hospital. Zhejiang University School Of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

I-A

I-B

I-C

I-D

I-E

Arm Description

LP002 dose escalation (3+3 design): 6-12 patients with malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment will receive LP002 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W), for up to 2 year.

If the safety profile in Arm A is acceptable, 9-12 patients with malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments will receive LP002 600mg or 900 mg IV on Day 1, Q2W, for up to 2 year.

If the safety profile in Arm A is acceptable, 15-20 patients with metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W,for up to 2 year.

Perioperative treatment: If the safety profile in Arm A is acceptable, 15-20 patients with gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W, for 3 cycles, 4-6 weeks before operation of the tumor and receive additional 6 cycles of the same therapy 4 weeks after the operation.

Dose escalation (3+3 design) of OH2 (an oncolytic virus) + LP002 900mg:If the safety profile in Arm A is acceptable, 15-30 patients with advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments will receive LP002 900mg IV on Day 1, Q2W, and OH2 10^6 or 10^7 or 10^8 CCID50/mL by intra-tumoral injection, Q2W, for up to 2 year.

Outcomes

Primary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Secondary Outcome Measures

Objective Response Rate (ORR) for Arm I-A, I-B, I-C, I-E
Percentage of subjects achieving complete response (CR) and partial response (PR). R0 resection rate RFS pCR
Disease Control Rate (DCR) for Arm I-A, I-B, I-C, I-E
Disease Control Rate (DCR) refers to the proportion of subjects who achieve CR, PR and SD through imaging evaluation.
Duration of Response (DOR) for Arm I-A, I-B, I-C, I-E
Duration of Response (DOR) is defined as the time from the first evidence of response (PR or CR) to the first evidence of PD or the date of death for any reason.
Progression-Free Survival (PFS) for Arm I-A, I-B, I-C, I-E
Progression-free survival (PFS) is defined as the time from the first study drug treatment to disease progression (PD) or to death of the subject due to any reason.
Overall survival (OS) for Arm I-A, I-B, I-C, I-D, I-E
Overall survival (OS) refers to the time from the first study drug treatment to death due to any cause.
R0 resection rate for Arm I-D
R0 resection rate refers to the rate of patients who have achieved curative resection of the tumor.(Curative resection refers to the absence of tumor after surgical treatment. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.)
pathological complete response rate (pCR rate)
pathological complete response rate (pCR rate) refers to the rate of patients whose tissue samples show no cancer cells left under a microscope after the anti-cancer treatment.
Terminal half life of LP002
Area under curve of LP002
Apparent volume of distribution of LP002
Systemic clearance of LP002
Cmax of LP002
Tmax of LP002
Serum concentration of the antibody against LP002 within 1 hour prior to each administration

Full Information

First Posted
February 1, 2021
Last Updated
February 12, 2021
Sponsor
Taizhou HoudeAoke Biomedical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04755543
Brief Title
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
Official Title
A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 17, 2019 (Actual)
Primary Completion Date
June 30, 2021 (Anticipated)
Study Completion Date
June 30, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taizhou HoudeAoke Biomedical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety, pharmacokinetics and preliminary efficacy of LP002 for the treatment of malignant digestive system neoplasms will be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Digestive System Neoplasms

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
94 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
I-A
Arm Type
Experimental
Arm Description
LP002 dose escalation (3+3 design): 6-12 patients with malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment will receive LP002 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W), for up to 2 year.
Arm Title
I-B
Arm Type
Experimental
Arm Description
If the safety profile in Arm A is acceptable, 9-12 patients with malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments will receive LP002 600mg or 900 mg IV on Day 1, Q2W, for up to 2 year.
Arm Title
I-C
Arm Type
Experimental
Arm Description
If the safety profile in Arm A is acceptable, 15-20 patients with metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W,for up to 2 year.
Arm Title
I-D
Arm Type
Experimental
Arm Description
Perioperative treatment: If the safety profile in Arm A is acceptable, 15-20 patients with gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W, for 3 cycles, 4-6 weeks before operation of the tumor and receive additional 6 cycles of the same therapy 4 weeks after the operation.
Arm Title
I-E
Arm Type
Experimental
Arm Description
Dose escalation (3+3 design) of OH2 (an oncolytic virus) + LP002 900mg:If the safety profile in Arm A is acceptable, 15-30 patients with advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments will receive LP002 900mg IV on Day 1, Q2W, and OH2 10^6 or 10^7 or 10^8 CCID50/mL by intra-tumoral injection, Q2W, for up to 2 year.
Intervention Type
Drug
Intervention Name(s)
LP002
Intervention Description
600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Intervention Description
50mg/m2 IV on Day 1, Q2W
Intervention Type
Drug
Intervention Name(s)
Fluorouracil
Intervention Description
2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
Intervention Type
Biological
Intervention Name(s)
OH2 oncolytic virus
Intervention Description
106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
Primary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame
up to approximately 24 months
Secondary Outcome Measure Information:
Title
Objective Response Rate (ORR) for Arm I-A, I-B, I-C, I-E
Description
Percentage of subjects achieving complete response (CR) and partial response (PR). R0 resection rate RFS pCR
Time Frame
up to approximately 24 months
Title
Disease Control Rate (DCR) for Arm I-A, I-B, I-C, I-E
Description
Disease Control Rate (DCR) refers to the proportion of subjects who achieve CR, PR and SD through imaging evaluation.
Time Frame
up to approximately 24 months
Title
Duration of Response (DOR) for Arm I-A, I-B, I-C, I-E
Description
Duration of Response (DOR) is defined as the time from the first evidence of response (PR or CR) to the first evidence of PD or the date of death for any reason.
Time Frame
up to approximately 24 months
Title
Progression-Free Survival (PFS) for Arm I-A, I-B, I-C, I-E
Description
Progression-free survival (PFS) is defined as the time from the first study drug treatment to disease progression (PD) or to death of the subject due to any reason.
Time Frame
up to approximately 24 months
Title
Overall survival (OS) for Arm I-A, I-B, I-C, I-D, I-E
Description
Overall survival (OS) refers to the time from the first study drug treatment to death due to any cause.
Time Frame
up to approximately 24 months
Title
R0 resection rate for Arm I-D
Description
R0 resection rate refers to the rate of patients who have achieved curative resection of the tumor.(Curative resection refers to the absence of tumor after surgical treatment. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed.)
Time Frame
up to approximately 12 months
Title
pathological complete response rate (pCR rate)
Description
pathological complete response rate (pCR rate) refers to the rate of patients whose tissue samples show no cancer cells left under a microscope after the anti-cancer treatment.
Time Frame
up to approximately 12 months
Title
Terminal half life of LP002
Time Frame
up to approximately 12 months
Title
Area under curve of LP002
Time Frame
up to approximately 12 months
Title
Apparent volume of distribution of LP002
Time Frame
up to approximately 12 months
Title
Systemic clearance of LP002
Time Frame
up to approximately 12 months
Title
Cmax of LP002
Time Frame
up to approximately 12 months
Title
Tmax of LP002
Time Frame
up to approximately 12 months
Title
Serum concentration of the antibody against LP002 within 1 hour prior to each administration
Time Frame
up to approximately 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Understood and signed an informed consent form. Age ≥ 18 and ≤ 75 years old, male or female. Has histologically confirmed diagnosis of: Malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment for Arm I-A. Malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments for Arm I-B. Metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive for Arm I-C. Gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive for Arm I-D. Advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments and has suitable lesions for intratumoral injection for Arm I-E. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Score. Life expectancy ≥ 3 months. Has at least one measurable extracranial lesion according to RECIST1.1 (except Arm-D). Has sufficient organ and bone marrow function to meet the following laboratory examination standards: Blood routine: absolute neutrophil count (ANC)≥1.5×10^9/L; while blood cell count (WBC)≥3×10^9/L; platelet count (PLT)≥100×10^9/L;hemoglobin (HGB)≥90 g/L; Renal function: Serum creatinine (Scr) ≤1.5×ULN; Liver function: TBIL≤1.5×ULN; Patients without liver metastases require alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN. Patients with liver metastases require: ALT and AST≤5×ULN; The coagulation function is adequate, which is defined as the international normalized ratio (INR) ≤ 2×ULN; or activated partial thromboplastin time (APTT)≤ 1.5×ULN; Reproductive men and women of childbearing age are willing to take effective contraceptive measures from signing the informed consent form to 3 months after the last administration of the trial drug. Willing to provide tissue samples for PD-L1 biomarker analysis. Exclusion Criteria: Suffered from other malignant tumors in the past 5 years,except those with low risk of metastasis and death (5-year survival rate >90%), for instance, skin basal cell carcinoma, squamous cell carcinoma, and carcinoma in situ from cervix or other regions that have been adequately treated); Had prior treatment with any anti-programmed cell death-1 (PD-1), or PD-ligand 1 (PD-L1) or CTLA-4 agent or other immune checkpoint inhibition therapies. has active or a history (with high chance of recurrence) of autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, vasculitis, nephritis, except: Type I Diabetes being treated with fixed dose of insulin, hypothyroidism or Hashimoto's thyroiditis that can be controlled only by hormone replacement therapy, skin diseases that do not require systemic treatment (such as eczema, rash covering <10% body surface area, psoriasis without ocular symptoms). Expected to undergo major surgery during the study treatment or within 28 days before the first administration of the study drug. Has received systemic corticosteroids or other immunosuppressive drugs within 2 weeks before the first administration of the study drug, excluding: Nasal spray, inhalation or other local glucocorticoids. Short-term (≤ 7 days) use of glucocorticoids as a preventive medication for allergic reactions or as a therapeutic medication for non-autoimmune diseases. Has active digestive ulcer, incomplete intestinal obstruction, active gastrointestinal hemorrhage or perforation. Has active interstitial pneumonia, pulmonary fibrosis, acute pulmonary disorders, acute radiation pneumonitis,et al. Has uncontrolled systemic diseases, for instance, cardiovascular and cerebrovascular disease, diabetes, tuberculosis. Has a history of HIV infection, or other acquired or innate immune deficiency disorders, or a history of organ or stem-cell transplantation. Has active chronic HBV or HCV infection, except those with HBV DNA viral load ≤500 IU/mL or <10^3 copies/mL, or HCV RNA negative after adequate treatment. Has severe infection within 4 weeks or active infection requiring IV infusion of antibiotics within 2 weeks prior to the first administration of the study drug. Known to be allergic to macromolecular protein agents or monoclonal antibody; Known to has a history of severe allergies to any of the components in the study drug; Has participated in other clinical trial within 4 weeks before the first administration of the study drug. Alcohol dependence or drug abuse within recent one year. Has a history of confirmed neurological or mental disorders, such as epilepsy, dementia; or with poor compliance; or the presence of peripheral neurological disorders. Has brain metastasis with symptoms. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial. Has received a live vaccine within 30 days prior to the first dose of trial treatment. Other reasons disqualifying the entering of this study based on the evaluation of the investigators.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jing Huang, MD
Phone
010-87788113
Email
huangjing@163.com
Facility Information:
Facility Name
Cancer Hospital Chinese Academy of Medical Sciences
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jing Huang, MD
Phone
010-87788113
Email
huangjing@163.com
Facility Name
Henan Cancer Hospital & Insititute
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Liu, MD
Email
yaya7207@126.com
Facility Name
Hubei Cancer Hospital & Insititute
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430070
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xinjun Liang, MD
Email
doctorlxj@163.com
Facility Name
Liaoning Cancer Hospital & Insititute
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110042
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jingdong Zhang, MD
Email
13804027878@163.com
Facility Name
The First Affiliated Hospital. Zhejiang University School Of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peng Zhao, MD
Email
haozhao@126.com
Facility Name
The First Affiliated Hospital. Zhejiang University School Of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qingwei Zhao, M.Pharm
Email
qwzhao@zju.edu.cn

12. IPD Sharing Statement

Learn more about this trial

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

We'll reach out to this number within 24 hrs